Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk fo...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Pharmacol Ther
Main Authors: Gammal, RS, Court, MH, Haidar, CE, Iwuchukwu, OF, Gaur, AH, Alvarellos, M, Guillemette, C, Lennox, JL, Whirl‐Carrillo, M, Brummel, SS, Ratain, MJ, Klein, TE, Schackman, BR, Caudle, KE, Haas, DW
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2015
主題:
CPIC Guidelines
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785051/
https://ncbi.nlm.nih.gov/pubmed/26417955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.269
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍